LOTT — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-20

• This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe-harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our strategy, market opportunity, pla…

• Forward-looking statements rest on management’s current expectations and are subject to substantial risks, uncertainties, and changes in circumstances that are outside the Company’s control. Actual results may differ materially. Important factors are described under the heading “Risk Factors” in our…

• We are a Nevada corporation whose common stock is quoted on the OTC Markets, OTCQB tier, under the symbol “APYP.” We currently operate in two areas: (i) the development and commercial deployment of a blockchain-based technology platform supporting licensed lottery, draw-based gaming, and casino-styl…

• Our blockchain-based technology is designed to support core lottery operational processes — including ticket registration, draw execution, and prize distribution — through smart-contract logic, verifiable randomness, and audit-trail capabilities intended to support regulatory and operator-side compl…

• While we intend to focus on the development and expansion of our lottery and gaming business, we continue to explore options with respect to our legacy digital health business.

Text removed vs the prior filing · source: 10-Q · 2025-11-19

• This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. In some cases, you can identify forward-looking…

• AppYea, Inc. is a digital health company, focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life.

• Our solutions are based on our proprietary intellectual property portfolio comprised of Artificial Intelligence (AI) and sensing technologies for the tracking, analysis, and diagnosis of vital signs and other physical parameters during sleep time, offering extreme accuracy at an affordable cost.AI i…

• As disclosed in our public filings, as of August 21, 2025 we have entered into a transaction with Techlott Enterprises Ltd. (“Techlott”), a Cypriot company, for the acquisition of proprietary blockchain-based lottery and gaming platform and the underlying intellectual property. The transaction with …

• Following on the heels of that announcement, on September 8, 2025, we issued a development update on our Techlott powered blockchain results engine regarding our plans to complete by the end of this year the adaptation of the platform to new and additional applications such that we can begin commerc…

Text added vs the prior filing · source: 10-Q · 2026-05-20

• As a smaller reporting company, the Company is not required to provide the information required by this Item.

Text removed vs the prior filing · source: 10-Q · 2025-11-19

• Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 31

• INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

• Condensed Consolidated Statements of Changes in Deficiency 7-10

• Notes to the Condensed Consolidated Financial Statements 12-20

• The accompanying notes are an integral part of the financial statements.

Text added vs the prior filing · source: 10-Q · 2026-05-20

• We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to ensure that information required to be disclosed in reports we file or submit under the Exchange Act is recorde…

• In connection with the preparation of this Quarterly Report on Form 10-Q, our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026. Based on that evaluation, our C…

• Material Weakness in Internal Control over Financial Reporting

• As disclosed in Item 9A of the 2025 10-K, our management identified a material weakness in our internal control over financial reporting relating to segregation of duties. Our management is composed of a small number of professionals, resulting in limitations on segregation of duties such that there…

• We continue to evaluate measures designed to remediate the material weakness, including the engagement of third-party accounting and reporting consultants to provide additional review of significant transactions and complex accounting matters. We expect to remain materially dependent on third-party …

Text removed vs the prior filing · source: 10-Q · 2025-11-19

• Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 31

• INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

• Condensed Consolidated Statements of Changes in Deficiency 7-10

• Notes to the Condensed Consolidated Financial Statements 12-20

• The accompanying notes are an integral part of the financial statements.

Text added vs the prior filing · source: 10-Q · 2026-05-20

• For information regarding our material legal proceedings, see Item 3 of our 2025 Annual Report on Form 10-K, which information is incorporated herein by reference. There have been no material developments in those proceedings during the three months ended March 31, 2026.

• Aside from the matter described in Item 3 of our 2025 10-K, from time to time we may become involved in various legal proceedings that arise in the ordinary course of business. Although the outcomes of legal proceedings cannot be predicted with certainty, we are not currently aware of any other lega…

Text removed vs the prior filing · source: 10-Q · 2025-11-19

• Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 31

• INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

• Condensed Consolidated Statements of Changes in Deficiency 7-10

• Notes to the Condensed Consolidated Financial Statements 12-20

• The accompanying notes are an integral part of the financial statements.

Text added vs the prior filing · source: 10-Q · 2026-05-20

• During the three months ended March 31, 2026, none of our directors or executive officers adopted, modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under…

Text removed vs the prior filing · source: 10-Q · 2025-11-19

• INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

• Condensed Consolidated Statements of Changes in Deficiency 7-10

• Notes to the Condensed Consolidated Financial Statements 12-20

• The accompanying notes are an integral part of the financial statements.

• Change in fair value of convertible loans and warrant liability (3,993) 139 (3,680) 31